Bruised Roche Wins Another UK Perjeta Round With Price Cut
In the latest round of what appears to have been a bruising set of price negotiations for Roche, the UK’s cost effectiveness agency NICE has recommended Perjeta in another breast cancer setting.
You may also be interested in...
The Scottish health technology assessment body, the SMC, has recommended a number of products for funding under NHS Scotland: Roche’s breast cancer drug Perjeta, Pfizer’s Xeljanz for psoriatic arthritis, and two antidiabetics, MSD’s Steglatro (ertugliflozin) and Novo Nordisk’s Ozempic (semaglutide).
While the National Institute for Health and Care Excellence has already backed Perjeta for certain indications, its new draft guidance has advised against NHS England using the drug after surgery for early breast cancer.
After okaying Roche's advanced breast cancer therapy Kadcyla after four years of deliberation, the UK's HTA body NICE will now decide how to respond to the Swiss group's proffered patient access scheme for Perjeta.